The most likely explanation is that the rate of events in the BIS were less than the DEN group.
Bisphosphonates MACE risk reduction are demonstrated in different trials. It's likely one of the explanations for the romosozumab "risk signal" which was absent in the placebo controlled trial but emerged when compared with alendronate.
The most likely explanation is that the rate of events in the BIS were less than the DEN group.
Bisphosphonates MACE risk reduction are demonstrated in different trials. It's likely one of the explanations for the romosozumab "risk signal" which was absent in the placebo controlled trial but emerged when compared with alendronate.